Table 1.
Clinical characteristics of 43 patients with ICC divided into three groups: those with metabolic components who were followed up, those with metabolic components who were not followed up, and those with no metabolic components
| Characteristic | Metabolic components (+) | Metabolic components (−) | p value | p value | |||
|---|---|---|---|---|---|---|---|
| Follow up group (a) | No follow group (b) | Control group (c) | (3 groups) | (2 groups) | |||
| (n=16) | (n=14) | (n=13) | a vs. b | a vs. c | b vs. c | ||
| Background | |||||||
| Age (years (range)) | 69 (56–79) | 66 (53–78) | 58 (46–82) | 0.163 | |||
| Gender (men/women) | 14/2 | 7/7 | 2/11 | 0.007* | 0.046* | 0.003* | 0.44 |
| Obesity (n (%)) | 10 (63%) | 5 (36%) | 0 (0%) | 0.002* | 0.272 | 0.000414* | 0.041* |
| DM (n (%)) | 5 (31%) | 2 (14%) | 0 (0%) | 0.074 | 0.399 | 0.048* | 0.481 |
| HT (n (%)) | 9 (56%) | 7 (50%) | 0 (0%) | 0.004* | 1.00 | 0.001* | 0.006* |
| Hyperlipidemia (n (%)) | 11 (69%) | 7 (50%) | 0 (0%) | 0.001* | 0.457 | 0.000129* | 0.006* |
| NAFLD (n (%)) | 13 (81%) | 5 (36%) | 2 (15%) | 0.001* | 0.024* | 0.001* | 0.385 |
| Brunt's classification | |||||||
| NAFL (Grade 0, Stage 0) | 2 (13%) | 0 (0%) | 0 (0%) | ||||
| NASH | |||||||
| Grade 1 Stage 0 | 2 (13%) | 0 (0%) | 0 (0%) | ||||
| Grade 1 Stage 1 | 4 (25%) | 5 (36%) | 2 (15%) | ||||
| Grade 1 Stage 3 | 1 (6%) | 0 (0%) | 0 (0%) | ||||
| Grade 2 Stage 1 | 2 (13%) | 0 (0%) | 0 (0%) | ||||
| Grade 2 Stage 2 | 2 (13%) | 0 (0%) | 0 (0%) | ||||
| Follow-up for metabolic factors | |||||||
| Abnormal laboratory test results (n (%)) | 6 (38%) | ||||||
| Abnormal findings on images (n (%)) | 7 (44%) | ||||||
| ICC-related symptoms (n (%)) | 3 (19%) | 10 (69%) | 9 (77%) | 0.0049* | 0.0086* | 0.0095* | 1.00 |
| Laboratory data | |||||||
| Total bilirubin (mg/dL) | 0.8 (0.5–1.5) | 0.7 (0.3–5.5) | 0.5 (0.3–1.0) | 0.028* | 0.854 | 0.008* | 0.061 |
| Albumin (g/dL) | 4.1 (3.0–4.6) | 4.2 (3.2–4.6) | 4.2 (3.4–4.8) | 0.742 | |||
| Prothrombin time (%) | 108 (81–128) | 104 (59–142) | 105 (79–117) | 0.608 | |||
| AST (IU/L) | 31 (19–104) | 29 (21–164) | 29 (13–130) | 0.881 | |||
| ALT (IU/L) | 26 (13–69) | 30 (9–208) | 30 (9–208) | 0.804 | |||
| Platelet count (×104/μL) | 19.9 (7.6–32.2) | 18.8 (13.9–29.4) | 24 (17.0–28.0) | 0.181 | |||
| γ-GTP (IU/L) | 62 (21–602) | 123 (18–531) | 107 (24–498) | 0.706 | |||
| Triglyceride (mg/dL) | 152 (52–372) | 125 (58–313) | 80 (60–110) | 0.004* | 0.377 | 0.001* | 0.043* |
| Glucose (mg/dL) | 104 (89–242) | 95 (81–131) | 92 (86–114) | 0.051 | 0.166 | 0.017* | 0.325 |
*
p value <0.05. Continuous values are expressed as median (range). Obesity=body mass index ≥25 kg/m2. AST=aspartate aminotransferase; ALT=alanine aminotransferase.